Download The Conference`s Scientific Program

THE CONFERENCE'S SCIENTIFIC PROGRAM:
Top leading scientists in the field of cancer research from Israel, Germany, France, Spain, Italy,
UK and the USA were invited to present their latest data. The meeting will also present cutting
edge cancer research technologies including genetically engineered mice, ex-vivo tissue
manipulation, novel imaging technologies, including molecule-targeted imaging and new
techniques in the field of cancer-stem-cell research. The lectures will link innate and adaptive
immunoregulatory mechanisms with carcinogenesis and cancer treatment by focusing on relevant
basic research, preclinical, translational and clinical issues.
Ten lectures will be selected from submitted abstracts.
INVITED SPEAKERS (in alphabetical order) – PRELIMINARY PROGRAM:

Abramovitch Rinat, Hadassah Hebrew University Hospital, Jerusalem, Israel
Double-strand DNA breaks - a key to liver tumor formation at a chronic inflammatory
state

Augustin Hellmut, DKFZ German Cancer Research Center, Heidelberg, Germany
Angiopoietin-2: Critical regulator of inflammation and hepatic homeostasis

Axelrod Jonathan, Hadassah Hebrew University Hospital, Jerusalem, Israel
IL-6 and chronic hepatitis-associated liver cancer

Apte Ron, Ben Gurion University of the Negev, Beer-Sheva
Interelukin-1-mediated inflammation and the malignant process

Balmain Allan, UCSF, California, USA
Genetic analysis of the opposing roles of inflammation in cancer

Baniyash Michal, The Hebrew University of Jerusalem, Jerusalem, Israel
Chronic inflammation-induced immunosuppression: Underlying mechanisms and clinical
implication in cancer

Barbacid Mariano, The Spanish National Cancer Research Center (CNIO), Madrid, Spain
Pancreatitis-induced inflammation and pancreatic ductal adenocarcinoma: A dangerous
liaison

Bartenschlager Ralf, University Hospital Heidelberg, Heidelberg, Germany
Hepatitis C virus-induced alterations promoting HCC development

Ben-Baruch Adit, Tel-Aviv University, Tel-Aviv, Israel
The inflammatory microenvironment in breast cancer: Regulation of a proangiogenic switch and cell-remodeling

Ben-Neriah Yinon, The Hebrew University of Jerusalem, Israel
Inflammatory control of colorectal cancer progression

Ben-Porath Ittai, The Hebrew University of Jerusalem, Jerusalem, Israel
Dynamics of generation and elimination of senescent cells in vivo

Breuhahn Kai, University Hospital Heidelberg, Heidelberg, Germany
Single-strand nucleic acid-binding proteins in hepatocarcinogenesis - regulation and
effector mechanisms

Buendia Marie Annick, INSERM U785, Paul Brousse Hospital, Villejuif, France
Hepatitis B and liver carcinogenesis: pending issues and controversies

Fehse Boris, Hamburg University, Hamburg, Germany
RGB marking for clonality assessment in liver regeneration and cancer

Feldmann Marc, University of Oxford, London, UK
TBD

Geiger Tamar, Tel-Aviv University, Tel-Aviv, Israel
Deep proteomic analysis of breast cancer

Gil Jesus, Imperial College London, London, UK
Non-cell-autonomous senescence

Goldenberg Daniel, Hadassah Hebrew University Hospital, Jerusalem, Israel
TBD

Heikenwälder Mathias, Technische Universität München (TUM), Helmholtz Zentrum
München, Munich, Germany
Distinct roles of the chemokine receptor CCR2 in tumor extravasation

Karin Michael, UC San Diego, San Diego, California, USA
TBD

Kühnel Florian, MHH Hannover Medical School, Hannover, Germany
Breaking tolerance: virus infections in tumors and tumor-directed immune responses

Levanon Erez, Bar Ilan University, Ramat-Gan, Israel
RNA editing, as a mechanism for somatic mutations induced by inflammation

Levy Carmit, Tel-Aviv University, Tel-Aviv, Israel
The three M's: Melanoma, MITF and microRNA

Malek Nisar, University Hospital, Tübingen, Germany
The role of ubiquitin ligases in the pathogenesis of liver cancer

Mandelboim Ofer, The Hebrew University of Jerusalem, Jerusalem, Israel
Control of innate immune responses by miRNAs

Mantovani Alberto, University of Milan, Milan, Italy
Targeting cancer-related inflammation

Peled Amnon, Hadassah Hebrew University Hospital, Jerusalem, Israel
Inflammation-induced hepatocellular carcinoma is dependent on the chemokine receptor
CCR5

Pikarsky Eli, The Hebrew University of Jerusalem, Jerusalem, Israel
Inflammatory signaling pathways in inflammation induced liver cancer

Rose-John Stefan, Christian-Albrechts-University of Kiel, Kiel, Germany
Pro-and anti-inflammatory properties of cytokines: A matter of cleavage

Sass Gabriele, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Induction of heme oxygenase 1 interferes with progression to fibrosis and cancer

Schrader Jorg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Inflammation-induced extracellular matrix alteration in liver cancer

Shaul Yosef, Weizmann Institute of Science, Rehovot, Israel
Study of intrinsically disordered proteins in designing a new approach in cancer therapy

Singer Stephan, University Hospital Heidelberg, Heidelberg, Germany
A nuclear core component regulates p53 target genes

Thorgeirsson Snorri S., National Institute of Health (NIH), Bethesda, Maryland, USA
Cancer and Stem Cells: A Fatal Attraction

Wagner Erwin F., The Spanish National Cancer Research Center (CNIO), Madrid, Spain
Inflammation and cancer: Functions of AP-1 (Fos/Jun)

Waxman David J., Boston University, Boston, Massachusetts, USA
Cytokine, chemokine and innate immune responses to metronomic chemotherapy

Wege Henning, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Transformation of telomerase-immortalized human hepatocytes – early steps of
hepatocarcinogenesis

Zender Lars, MHH Hannover Medical School, Hannover and HZI Helmholtz Center,
Braunschweig, Germany
Senescence surveillance in hepatocellular carcinoma